Description
14330-1-AP targets ADAR1 in WB, IHC, IF/ICC, IP, CoIP, ELISA applications and shows reactivity with human, mouse, rat, pig samples.
Tested Applications
Positive WB detected in: HeLa cells, A431 cells, HepG2 cells, Jurkat cells
Positive IP detected in: HepG2 cells
Positive IHC detected in: human colon cancer tissue, human gliomas tissue, human stomach cancer tissue, mouse brain tissue, mouse colon tissueNote: suggested antigen retrieval withTE buffer pH 9.0;(*) Alternatively, antigen retrieval may be performed withcitrate buffer pH 6.0
Positive IF/ICC detected in: HeLa cells
Recommended dilution
Western Blot (WB): WB : 1:500-1:2000
Immunoprecipitation (IP): IP : 0.5-4.0 ug for 1.0-3.0 mg of total protein lysate
Immunohistochemistry (IHC): IHC : 1:50-1:500
Immunofluorescence (IF)/ICC: IF/ICC : 1:200-1:800
Background Information
ADAR1 is also named as ADAR1, DSRAD, G1P1, IFI4. It convert selected adenosine residues into inosine in substrate RNAs containing a relatively short dsRNA region(PMID:15556947). The human ADAR1 gene specifies two size forms of RNA-specific adenosine deaminase, an IFN inducible ∼150 kDa protein and a constitutively expressed N-terminally truncated ∼110 kDa protein, encoded by transcripts with alternative exon 1 structures that initiate from different promoters(PMID:11111054). It has 5 isoforms produced by alternative promoter usage and alternative splicing. Defects in ADAR are a cause of dyschromatosis symmetrical hereditaria (DSH).ADAR1 can form respective homodimers, and this association is essential for its enzymatic activities(PMID:17428802).